New drug cocktail shows promise against tough breast cancer

NCT ID NCT04039230

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study tests a combination of two drugs—sacituzumab govitecan and talazoparib—in people with metastatic triple-negative breast cancer that has spread. The goal is to see if the combo can shrink tumors or slow the disease. About 75 adults with advanced cancer are taking part. This is an early-phase trial focused on safety and effectiveness, not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Boston Medical Center

Boston, Massachusetts, 02118, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.